膵臓移植と悪性腫瘍

抄録

In Japan, 555 pancreatic transplants were performed between 2004 and 2023. Although the transplant outcomes were good, 29 patients (32 cases) developed de novo malignancy after transplantation. The most common was PTLD, accounting for approximately 30% of the total. Although the occurrence of malignant tumors does not significantly decrease patient survival rates or graft survival rates, it may affect patient survival and graft survival 5 years or more after transplantation. In addition, 72 deaths were recorded out of 555 cases, and malignant tumors were the third most common cause of death after infections and heart disease. At Fujita Health University Hospital, 7 out of 119 cases developed de novo malignancy after pancreatic transplantation, and one patient died. It is important to avoid over immunosuppression after transplantation, and regular screening for de novo malignancy is essential for improving the outcome of pancreatic transplantation.